111 related articles for article (PubMed ID: 8774398)
41. Thrombolysis for acute ischaemic stroke.
Wardlaw JM; del Zoppo G; Yamaguchi T
Cochrane Database Syst Rev; 2000; (2):CD000213. PubMed ID: 10796329
[TBL] [Abstract][Full Text] [Related]
42. [Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
Warlow C
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(2):47-50. PubMed ID: 10081136
[No Abstract] [Full Text] [Related]
43. Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis.
Büttner T; Hellwig K; Müller T; Kuhn W
Clin Neuropharmacol; 1998; 21(1):48-51. PubMed ID: 9579285
[TBL] [Abstract][Full Text] [Related]
44. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
[TBL] [Abstract][Full Text] [Related]
45. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study.
Biller J; Bruno A; Adams HP; Godersky JC; Loftus CM; Mitchell VL; Banwart KJ; Jones MP
Stroke; 1989 Apr; 20(4):441-7. PubMed ID: 2648650
[TBL] [Abstract][Full Text] [Related]
46. Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation.
Wardlaw JM; West TM; Sandercock PA; Lewis SC; Mielke O;
J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):452-8. PubMed ID: 12640062
[TBL] [Abstract][Full Text] [Related]
47. The International Stroke Trial database.
Sandercock PA; Niewada M; Członkowska A;
Trials; 2011 Apr; 12():101. PubMed ID: 21510853
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin.
Chamorro A; Obach V; Vila N; Revilla M; Cervera A; Ascaso C
J Neurol Sci; 2000 Sep; 178(1):17-22. PubMed ID: 11018244
[TBL] [Abstract][Full Text] [Related]
49. Early management and outcome of acute stroke in Auckland.
Anderson NE; Bonita R; Broad JB
Aust N Z J Med; 1997 Oct; 27(5):561-7. PubMed ID: 9404588
[TBL] [Abstract][Full Text] [Related]
50. Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke.
Kay R; Wong KS; Woo J
Stroke; 1994 Mar; 25(3):684-5. PubMed ID: 8128526
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study.
Rödén-Jüllig A; Britton M
J Intern Med; 2000 Oct; 248(4):287-91. PubMed ID: 11086638
[TBL] [Abstract][Full Text] [Related]
52. Counterfactual clinical prediction models could help to infer individualized treatment effects in randomized controlled trials-An illustration with the International Stroke Trial.
Nguyen TL; Collins GS; Landais P; Le Manach Y
J Clin Epidemiol; 2020 Sep; 125():47-56. PubMed ID: 32464321
[TBL] [Abstract][Full Text] [Related]
53. Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop.
Hankey GJ
Med J Aust; 1998 Nov; 169(10):534-6. PubMed ID: 9861911
[TBL] [Abstract][Full Text] [Related]
54. Variations between countries in outcome after stroke in the International Stroke Trial (IST).
Weir NU; Sandercock PA; Lewis SC; Signorini DF; Warlow CP
Stroke; 2001 Jun; 32(6):1370-7. PubMed ID: 11387501
[TBL] [Abstract][Full Text] [Related]
55. Safety of heparin in acute ischemic stroke.
Hart RG; Boop BS; Tong DC; Yenari MA; Albers GW
Neurology; 1996 Feb; 46(2):589; author reply 589-91. PubMed ID: 8614549
[No Abstract] [Full Text] [Related]
56. Intravenous heparin for acute stroke: what can we learn from the megatrials?
Swanson RA
Neurology; 1999 Jun; 52(9):1746-50. PubMed ID: 10371518
[TBL] [Abstract][Full Text] [Related]
57. Heparin during aneurysm repair.
Vahl AC; Mackaay AJ
Eur J Vasc Endovasc Surg; 1997 Apr; 13(4):425. PubMed ID: 9134001
[No Abstract] [Full Text] [Related]
58. [What is the remaining role of heparin in the treatment of acute cerebral ischemia?].
Touzé E; Arquizan C; Mas JL
Rev Neurol (Paris); 2004 Jul; 160(6-7):728-35. PubMed ID: 15247866
[No Abstract] [Full Text] [Related]
59. Mast trials.
Wardlaw JM
J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):255-6. PubMed ID: 8126525
[No Abstract] [Full Text] [Related]
60. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].
Peterson B; George SL
Control Clin Trials; 1993 Dec; 14(6):511-22. PubMed ID: 8119066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
